Page last updated: 2024-08-17

adenosine diphosphate and prasugrel hydrochloride

adenosine diphosphate has been researched along with prasugrel hydrochloride in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	21 (32.81)	29.6817
2010's	38 (59.38)	24.3611
2020's	5 (7.81)	2.80

Authors

Authors	Studies
Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A	1
Asai, F; Iwamura, R; Koike, H; Ogawa, T; Otsuguro, K; Sugidachi, A; Yoneda, K	1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A	1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, GY; Naganuma, H; Payne, CD; Small, DS; Weerakkody, GJ; Winters, KJ	1
Asai, F; Brandt, JT; Freestone, S; Hirota, T; Jakubowski, JA; Matsushima, N; Naganuma, H; Winters, KJ	1
Bliden, KP; Gurbel, PA; Tantry, US	1
Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ	1
Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A	1
Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Winters, KJ	1
Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ	1
Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Tarnow, I; Winters, KJ	1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	2
Brandt, JT; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Weerakkody, GJ; Winters, KJ	1
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A	1
Dovlatova, N; Heptinstall, S; Johnson, A	1
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP	1
Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Winters, KJ; Wrishko, RE	1
Farid, NA; Jakubowski, JA; Kothare, P; Lachno, DR; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Thieu, VT; Winters, KJ; Yuen, E	1
del Río, A; Heras, M	1
Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G	1
Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ	1
Cattaneo, M	2
Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y	1
Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE	1
Behr, T; Behr, W; Kuch, B; von Scheidt, W	1
Antman, EM; Braunwald, E; Costigan, TM; Frelinger, AL; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Neumann, FJ; Trenk, D; Wiviott, SD	1
Aradi, D; Atar, D; Kuliczkowski, W; Serebruany, VL	1
Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM	1
Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M	1
Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Angiolillo, DJ; Bass, TA; Desai, B; Ferreiro, JL; Guzman, LA; Rollini, F; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M	1
Choi, HC; Gu, N; Kawakatsu, E; Kelly, RP; Park, KW; Payne, C; Pinton, P; Small, DS; Yu, KS	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S	1
Cui, Y; Xiang, Q; Zhao, N; Zhao, X	1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE	1
Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A	3
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE	1
Frelinger, AL; Gupta, N; Howard, J; Jakubowski, JA; Jurcevic, S; Lachno, DR; Mant, TG; Payne, CD; Winters, KJ; Zhou, C	1
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X	1
Frelinger, AL; Howard, J; Jakubowski, JA; Jurcevic, S; Lachno, DR; Mant, T; Payne, CD; Winters, KJ; Zhou, C	1
Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L	1
Baaten, CC; Crijns, H; de Witt, SM; Heemskerk, JW; Henskens, YM; Nylander, S; Swieringa, F; van der Meijden, PE; van Geffen, JP; van Giezen, JJ; Veenstra, LF; Wetzels, R	1
Banya, W; Booth, J; Dalby, M; Davidson, SJ; Droppa, M; Flather, M; Gawaz, M; Geisler, T; Karathanos, A; Müller, K; Stables, RH; Tavlaki, E; Yanez-Lopez, M; Zaman, A	1
Akca, B; Berger, R; Delle-Karth, G; Kreiner, G; Lang, IM; Maurer, G; Neunteufl, T; Siller-Matula, JM	1
Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D	1
Anstrom, KJ; Effron, MB; Faries, DE; Federspiel, JJ; Mauri, L; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Yeh, RW; Zettler, M	1
Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C	1
Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM	1
Li, L; Li, Y; Lu, N; Meng, F; Wei, Q; Xu, Y; Yuan, J; Zhang, S; Zheng, X	1
Brunner, S; Hamm, W; Lackermair, K; Mehr, M; Rizas, K	1
Barbato, E; Bartunek, J; Bressi, E; Bruyne, B; Di Gioia, G; Di Serafino, L; Mangiacapra, F; Morisco, C; Peace, AJ; Pellicano, M; Wijns, W	1
Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D	1
Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP	1
Bliden, KP; Dahlen, J; Fisher, R; Gurbel, PA; Speros, PC; Sukavaneshvar, S; Tantry, US	1
Boncler, M; Palma, A; Watala, C; Wzorek, J	1
Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM	1
Baron, SJ; Dani, SS; Ganatra, S; Ijaz, SH; Kulbak, G; Levy, M; Resnic, F; Shahnawaz, A	1

Reviews

7 review(s) available for adenosine diphosphate and prasugrel hydrochloride

Article	Year
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine	2005
Prasugrel. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12 Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2006
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Bayes Theorem; Clinical Trials, Phase I as Topic; Clopidogrel; Databases, Factual; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2007
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood, 2011, Feb-17, Volume: 117, Issue:7 Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine	2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries. Current problems in cardiology, 2023, Volume: 48, Issue:5 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Humans; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; United States	2023

Trials

26 trial(s) available for adenosine diphosphate and prasugrel hydrochloride

Article	Year
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:3 Topics: Adenosine Diphosphate; Adult; Bleeding Time; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2006
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets, 2006, Volume: 17, Issue:4 Topics: Adenosine Diphosphate; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Time Factors	2006
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:5 Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Light; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Thiophenes; Ticlopidine; Time Factors	2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of clinical pharmacology, 2008, Volume: 48, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine	2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets, 2008, Volume: 19, Issue:4 Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European heart journal, 2009, Volume: 30, Issue:14 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. Drugs & aging, 2009, Volume: 26, Issue:9 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aging; Aspirin; Bleeding Time; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Fasting; Female; Humans; Least-Squares Analysis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Statistics, Nonparametric; Tablets, Enteric-Coated; Thiophenes; Young Adult	2009
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. European journal of clinical pharmacology, 2010, Volume: 66, Issue:2 Topics: Adenosine Diphosphate; Adult; Aged; Asian People; Body Mass Index; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Statistics as Topic; Thiophenes; White People; Young Adult	2010
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thrombosis and haemostasis, 2010, Volume: 103, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2010
Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Platelets, 2010, Volume: 21, Issue:8 Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Blood Platelets; Clopidogrel; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thromboxanes; Ticlopidine; Young Adult	2010
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thrombosis and haemostasis, 2011, Volume: 106, Issue:2 Topics: Adenosine Diphosphate; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2011
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11 Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2012
Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:2 Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome	2013
Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Drug Administration Schedule; Drug Resistance; Humans; Microfilament Proteins; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Time Factors; Treatment Outcome	2013
Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. Journal of cardiovascular pharmacology, 2013, Volume: 62, Issue:1 Topics: Adenosine Diphosphate; Adult; Area Under Curve; Asian People; Biotransformation; Blood Platelets; Chromatography, High Pressure Liquid; Humans; Male; Mass Spectrometry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Treatment Outcome; Young Adult	2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis research, 2014, Volume: 133, Issue:2 Topics: Adenosine Diphosphate; Adult; Anemia, Sickle Cell; Biomarkers; Blood Coagulation; Blood Platelets; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Young Adult	2014
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion, 2015, Volume: 55, Issue:6 Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication. Haematologica, 2015, Volume: 100, Issue:9 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Blood Coagulation; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12	2015
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PloS one, 2015, Volume: 10, Issue:8 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Treatment Outcome	2015
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets, 2016, Volume: 27, Issue:8 Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor. Thrombosis and haemostasis, 2018, Volume: 118, Issue:2 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor	2018
Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis, 2018, Volume: 278 Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Pyridines; Troponin T	2018
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Thrombosis and haemostasis, 2019, Volume: 119, Issue:4 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Circadian Rhythm; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Time Factors	2019
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease. Journal of thrombosis and thrombolysis, 2022, Volume: 54, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor	2022

Other Studies

31 other study(ies) available for adenosine diphosphate and prasugrel hydrochloride

Article	Year
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British journal of pharmacology, 2000, Volume: 129, Issue:7 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium	2000
Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. British journal of pharmacology, 2001, Volume: 132, Issue:1 Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Calcium; Cyclic AMP; Cyclopropanes; Fibrinogen; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; In Vitro Techniques; Male; Membrane Proteins; Piperazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes	2001
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:7 Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine	2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and haemostasis, 2007, Volume: 98, Issue:1 Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Humans; Inflammation; Kinetics; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis; Up-Regulation	2007
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:2 Topics: Adenosine Diphosphate; Annexin A5; Biotransformation; Blood Coagulation Factors; Blood Platelets; Clot Retraction; Collagen; Humans; Monocytes; Phosphatidylserines; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Thrombin; Thromboplastin	2008
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:7 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
Multiple electrode aggregometry and P2Y(12) antagonists. Thrombosis and haemostasis, 2008, Volume: 99, Issue:6 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine	2009
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:2 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor	2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2011
Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and haemostasis, 2012, Volume: 107, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clinical Protocols; Female; Humans; Male; Middle Aged; Observer Variation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Proton Pump Inhibitors; Thiophenes	2012
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thrombosis research, 2012, Volume: 130, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine	2012
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine	2013
Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics, 2013, Volume: 14, Issue:10 Topics: Adenosine Diphosphate; Adult; Blood Platelets; Female; Humans; Male; Pharmacogenetics; Piperazines; Platelet Aggregation; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Receptors, Cell Surface; Thiophenes	2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Thrombosis and haemostasis, 2013, Volume: 110, Issue:4 Topics: Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Pilot Projects; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. Thrombosis and haemostasis, 2013, Volume: 110, Issue:4 Topics: Adenosine; Adenosine Diphosphate; Administration, Oral; Adult; Animals; Cell Adhesion Molecules; Clinical Protocols; Enzyme-Linked Immunosorbent Assay; Humans; Macaca fascicularis; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Young Adult	2013
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thrombosis and haemostasis, 2014, Mar-03, Volume: 111, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine	2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248 Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency	2014
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets, 2015, Volume: 26, Issue:5 Topics: Adenosine Diphosphate; Adult; Anemia, Sickle Cell; Biomarkers; Blood Platelets; Case-Control Studies; Female; Humans; Leukocytes; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Young Adult	2015
Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis. Thrombosis research, 2015, Volume: 136, Issue:6 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Haplorhini; Hemorrhage; Infarction, Middle Cerebral Artery; Macaca fascicularis; Male; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thrombosis; Time Factors	2015
Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice. Thrombosis research, 2015, Volume: 136, Issue:6 Topics: Adenosine Diphosphate; Animals; Aorta; Arterial Occlusive Diseases; Arteries; Carotid Arteries; Chemokine CCL2; Chlorides; Ferric Compounds; Hyperplasia; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; Neointima; Platelet Aggregation; Prasugrel Hydrochloride; Pyridines; RNA, Messenger; Thrombosis; Time Factors; Transforming Growth Factor beta1	2015
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets, 2016, Volume: 27, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Biomarkers; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Ticagrelor; Treatment Outcome	2016
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA cardiology, 2016, Sep-01, Volume: 1, Issue:6 Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome	2016
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after American heart journal, 2017, Volume: 183 Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine	2017
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. European journal of clinical investigation, 2018, Volume: 48, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine	2018
Synthesis of a Novel Series of Amino Acid Prodrugs Based on Thienopyridine Scaffolds and Evaluation of Their Antiplatelet Activity. Molecules (Basel, Switzerland), 2018, Apr-28, Volume: 23, Issue:5 Topics: Adenosine Diphosphate; Animals; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Molecular Structure; Platelet Aggregation; Prasugrel Hydrochloride; Prodrugs; Rats; Thienopyridines; Ticlopidine	2018
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy. International journal of sports medicine, 2018, Volume: 39, Issue:8 Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiography; Exercise; Exercise Tolerance; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticlopidine	2018
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. European journal of clinical investigation, 2020, Volume: 50, Issue:11 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor	2020
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor	2021
A comparison of different regression models for the quantitative analysis of the combined effect of P2Y Thrombosis research, 2022, Volume: 211 Topics: Adenosine Diphosphate; Blood Platelets; Humans; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12	2022